, University of Miami Metabolic & weight loss medicine Dr
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
Their health profiles could not be more different
For more practical tips to help you put this into action, check out our guides to increasing your fibre intake and choosing high-protein snacks
Semaglutide is FDA-approved for multiple indications: as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Feature: Targets: Semaglutide: GLP-1 Tirzepatide: GLP-1 + GIP Retatrutide: GLP-1 + GIP + Glucagon Max Weight Loss: Semaglutide: ~15% Tirzepatide: ~22% Retatrutide: 24.2%+ Energy Expenditure: Semaglutide: Low Tirzepatide: Moderate Retatrutide: High Muscle Preservation: Semaglutide: Moderate Tirzepatide: Moderate Retatrutide: Better Dosing Frequency: All: Weekly The addition of glucagon receptor activation gives Retatrutide a unique fat-burning advantage, making it ideal for visceral fat reduction and metabolic reset protocols
